How to Group Multiple Models for Overseas Registration of Implantable Medical Devices

Published: August 28, 2026 | Updated: August 28, 2026

Executive Summary

For implantable medical devices, grouping multiple models into a single registration application is a common way to reduce costs and improve efficiency. However, different countries do not consistently define the concept of a "series" or "family." Manufacturers should first determine whether the product falls within the target country's medical device regulatory scope, then identify the applicant according to risk class and registration pathway, and then assess whether existing NMPA, CE, FDA, or ISO 13485 technical documents can be reused. The core of grouped submission is not simply combining all models; it is to establish a technical equivalence evidence chain, including difference analyses of design specifications, materials, sterilization methods, indications, clinical evaluation, labels, and instructions for use. If key differences among models affect safety or effectiveness, forced grouping should be avoided. Manufacturers must also clarify the responsibilities of the local agent or authorized representative, and implement post-market surveillance, adverse event reporting, and certificate maintenance mechanisms. Common risks include improper reuse of documentation, omission of variant models, and loss of certificate control after changing agents. It is recommended to conduct an early feasibility assessment, prioritize building a technical file for the core model, and then expand to multi-country submissions through difference comparisons, thereby reducing the risk of repeated compilation and deficiency responses. This article is compiled from the AIMEILI Regulatory Practice Database, the Medical Device International Registration Knowledge Base, and public regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product documentation basis.

Applicable Scenarios and Core Questions

In overseas registration of implantable products, manufacturers often face a practical issue: a product series contains multiple models, such as bone screws, plates, implants, or cardiac interventional devices with different lengths, diameters, angles, or coating designs. The company wants to cover all models with one registration unit to reduce fees and shorten review time, but different regulatory bodies differ in their acceptance of this approach.

This scenario is particularly relevant for registration in GHWP member countries, as well as multi-country projects in Southeast Asia, the Middle East, and Latin America. Manufacturers must first clarify whether the target country allows "series" or "family" submissions and what scope is permitted. Experience from China's NMPA or CE registration cannot be directly applied.

The core question is not "can we submit together?" but "which variables can be grouped and which must be submitted separately?" This involves registration unit division, representative model selection, technical equivalence justification, local agent arrangements, and post-market maintenance responsibilities.

Registration Decision Logic

First, determine whether the product is within the target country's medical device regulatory scope. Implantable products are generally classified as high-risk or medium-to-high-risk devices, but definitions and exclusion lists vary. For example, some countries treat certain dental implants as ordinary medical devices, while others require them to be regulated as drugs.

Second, determine the risk class, registration pathway, and applicant. Most implantable products in GHWP member countries fall under Class II or Class III, and may require third-party review, national review, or a combination. The applicant is usually the local registrant, so a local agent or authorized representative must be appointed.

Third, assess whether existing documentation can be reused. Manufacturers should take stock of existing NMPA registration certificates, CE technical files, FDA 510(k) or PMA submissions, ISO 13485 quality system certificates, MDSAP certificates, and clinical evaluation reports, and perform a gap analysis against target country requirements.

Fourth, confirm the technical basis for grouping. Grouped submission is typically based on the premise of the same design architecture, same material system, same sterilization method, same indications, and differences that do not affect safety or effectiveness. Manufacturers need to build a difference matrix among models, showing which parameters are within range and which differences require coverage through performance verification or clinical evidence.

Fifth, confirm local requirements, including whether the final labeling and instructions for use need to be in the local language, whether local clinical trials are required, whether sample testing is required, how the local agent's control over the registration certificate is arranged, and how renewal and changes are linked.

Documentation and Evidence

Grouped submission does not mean less documentation. The manufacturer still needs to submit a complete registration dossier, but the main technical file can be organized around a "core model," with other models covered through difference analysis.

Key documentation includes: product design description and specification table, material composition and biocompatibility report, sterilization validation, shelf-life validation, performance test report, risk management file, clinical evaluation or clinical evidence, labels and instructions for use, and quality system certification.

For multi-country projects, core technical files should be organized according to the IMDRF nomenclature directory to facilitate reuse among GHWP members. However, each country will impose local conversion requirements such as language, standard references, statutory format, and local agent declarations.

• Master document: product technical file with an overview and difference description for all models.
• Difference matrix: compare design parameters, materials, dimensions, packaging, and indications across all models.
• Equivalence justification: demonstrate that differences do not affect safety or effectiveness; provide test data when necessary.
• Representative model selection rationale: explain why a particular model can serve as the typical product for biocompatibility, fatigue, or clinical evaluation.
• Risk management report: cover risk analysis for all models, not just a single model.
• Labels and instructions for use: either independent versions for each model or a series-wide version that meets local language requirements.
• Local agent authorization documents: define the scope of authorization, renewal, and replacement constraints.
• Post-market surveillance plan and adverse event reporting pathway.

Common Errors

Manufacturers often make the following mistakes when submitting multiple models in one group; these should be avoided in advance.

• Putting all models into one registration unit without considering technical differences, resulting in deficiency letters from the reviewing authority.
• Lack of a difference matrix or incomplete difference analysis, leaving reviewers unable to judge equivalence among models.
• Selecting an inappropriate representative model, such as the most complex model with minimal actual clinical use, increasing unnecessary testing costs.
• Directly applying CE grouping conclusions to other countries without considering local definitions and evidence requirements for a "series."
• Failing to cover all models in the technical documentation, and reviewers discover missing parameters or validation data for a specific model.
• Labels and instructions for use show only the series name without listing each model and specification, causing customs clearance and post-market compliance problems.
• Ignoring the local agent's role in grouped submission; the agent does not have the complete file, leaving changes and renewals passive.
• The post-market surveillance plan does not correspond one-to-one with the grouped models, making it impossible to locate the specific model when adverse events occur.

Manufacturer Preparation Checklist

To increase the success rate of grouped submission, manufacturers should implement the following preparations before project initiation.

• List target countries and confirm each country's specific rules and fees for grouped submission.
• Build a master model list and difference matrix, identifying which models belong to the same technical platform.
• Take stock of existing registration certificates, test reports, ISO 13485 certificates, and clinical evidence, and assess reusability.
• Determine the core model and representative model, and prepare a supplementary testing plan.
• Adjust labels and instructions for use according to target country regulatory requirements, and prepare local language versions.
• Appoint or replace the local agent, sign the authorization agreement, and define the boundary of certificate control.
• Establish a post-market surveillance database and conduct adverse event monitoring by model group.
• Arrange internal regulatory meetings, track multi-country submission progress by milestone, and reserve time for deficiency responses.

AIMEILI Regulatory Interpretation and Business Impact

The most common misjudgment is assuming that submitting multiple models together will always be cheaper and faster than submitting each model separately. In reality, if the grouping justification is insufficient, a single deficiency letter can disrupt the entire plan. AIMEILI believes that the most valuable investment in the early stage of a project is not writing more generic documents, but conducting a rigorous grouping feasibility assessment to determine which models can share evidence and which must be split or require additional verification.

The core logic is to reuse as much as possible while never skipping mandatory local requirements. General parts of the technical file, such as material characterization, sterilization validation, and risk management frameworks, can be reused across markets. However, the legal entity, authorized representative, language versions, clinical data acceptance, and local submission format must be adjusted for each target country.

Local agent and certificate control are extremely important. Many manufacturers discover after changing agents that the original certificate cannot be easily canceled or transferred, resulting in interrupted registration in multiple countries. A written agreement should be in place from the beginning, specifying change, renewal, and termination procedures. Multi-country registration is not repetitive labor; it is one core file plus multiple local shells. AIMEILI recommends building a traceable modular system centered on the registration technical file, with each country's review comments and supplementary data fed back into the master file. This significantly reduces the risk of rework and deficiency responses.

Common Follow-up Questions

Which models can be placed in the same registration group?

Generally, models can be grouped when they come from the same manufacturer, share the same design principle, use the same materials and sterilization method, have dimensional or other parameter differences that do not affect safety or effectiveness, and have no substantive difference in indications. For questionable differences, it is best to confirm through pre-submission communication or consultation with the local agent.

If some models do not have their own clinical data, can data from a representative model be used?

Yes, but a full equivalence justification is required. You should explain the basis for selecting the representative model, show the difference matrix between other models and the representative model, and prove that these differences do not change biocompatibility, mechanical performance, or clinical outcomes. Some countries may also require additional testing or literature support.

After grouped submission, does adding a new model require re-registration?

It depends on whether the new model falls within the original registration scope. If it is still on the same technical platform and meets equivalence conditions, most countries allow adding the model through a change notification or change application, but the detailed national rules must be confirmed in advance. If the difference is significant, a new registration application may be required.

Related Reading

• Why Does the Registration Cycle for Laboratory Equipment Overseas Registration Extend?
• How to Choose a Local Agent for Overseas Registration of Disinfection and Sterilization Equipment?
• How Are Authorized Representative Responsibilities Divided for Overseas Registration of Disinfection and Sterilization Equipment?
• What Are Common Reasons for Deficiency Responses in Overseas Registration of Disinfection and Sterilization Equipment?
• What Should Be Prepared Before Renewal of Overseas Registration for Disinfection and Sterilization Equipment?
• How to Group Multiple Models for Overseas Registration of Disinfection and Sterilization Equipment?

Review and Applicability

Content author: AIMEILI Regulatory Editorial Department. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: Priority is given to official regulatory authorities, international organizations, standards bodies, and public regulatory materials; industry media and project experience are used only as auxiliary reference. Applicability: This article is for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements, testing conclusions, or legal opinions of the target country's regulatory authority.